<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00352976</url>
  </required_header>
  <id_info>
    <org_study_id>MT2006-05</org_study_id>
    <secondary_id>0605M85788</secondary_id>
    <nct_id>NCT00352976</nct_id>
  </id_info>
  <brief_title>TBI Dose De-escalation for Fanconi Anemia</brief_title>
  <official_title>Total Body Irradiation Dose De-escalation Study in Patients With Fanconi Anemia Undergoing Alternate Donor Hematopoietic Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm, total body irradiation (TBI) trial. All patients will be prescribed TBI
      300 cGy with the goal of evaluating secondary endpoints.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Treatment: Patients will receive voriconazole (antifungal therapy) by mouth beginning 1
      month prior to conditioning therapy, if possible. 1) The subject is to receive total body
      irradiation (300 cGy) with thymic shielding; it will be given six days before the stem cells
      are given (day -6). 2) Day -5 through Day -2, subjects will receive a chemotherapy regimen of
      Fludarabine and Cyclophosphamide via central line (i.e. Hickman or Broviac). Starting Day -3,
      patients will receive sirolimus therapy with a taper commencing on day +180 and also
      mycophenolate mofetil (MMF) through day +30 or for 7 days after engraftment, whichever day is
      later, if no acute graft-versus-host disease (GVHD). 4) If the subject is receiving bone
      marrow or &quot;peripheral&quot; stem cells (cells collected from the donor's arm via a cell
      separator), on the day of transplantation, the stem cells taken from the donor will be put
      into a machine which will separate the lymphocytes (the cells that cause graft-versus-host
      disease [GVHD]) from the stem cells. If the subject is receiving an umbilical cord blood, the
      lymphocytes will not be removed because the risk of GVHD is not as high. Otherwise all
      patients will receive the same treatment. The stem cells are given as an infusion into the
      subject's existing catheter over 1-2 hours on day 0.5. On the day after transplant (day +1)
      subjects will be given G-CSF to stimulate the growth of the transplanted cells. 6. While
      receiving treatment and until the subject's blood counts recover he/she will have daily blood
      tests, and several bone marrow biopsies and aspirates. After recovery, subjects will be seen
      once a month for a health assessment and blood tests until at least 3 months after the cells
      have been infused. Additional blood tests or assessments may be done as medically indicated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 18, 2006</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of neutrophil recovery (absolute neutrophil count ≥500/µL for three consecutive days) .</measure>
    <time_frame>by day 42</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of grade ≥3 regimen related toxicity .</measure>
    <time_frame>at day 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of secondary graft failure at 100 days.</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute graft-versus-host disease (GVHD)</measure>
    <time_frame>at 100 days.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of chronic GVHD .</measure>
    <time_frame>at one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Probability of survival .</measure>
    <time_frame>at one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of infections .</measure>
    <time_frame>at 100 days, 6 months and one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune reconstitution .</measure>
    <time_frame>at 100 days, 6 month and one year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Fanconi Anemia</condition>
  <arm_group>
    <arm_group_label>Treatment with TBI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients treated with total body irradiation, Fludarabine, Cyclophosphamide, Bone Marrow Transplantation, Mycophenolate Mofetil, and Sirolimus.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Day -5 through Day -2, subjects will receive chemotherapy of Cyclophosphamide via central line (i.e. Hickman or Broviac),10 mg/kg intravenously (IV)</description>
    <arm_group_label>Treatment with TBI</arm_group_label>
    <other_name>cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Day -5 through Day -2 prior to transplant; subjects will receive chemotherapy of Fludarabine via central line (i.e. Hickman or Broviac),35 mg/m^2 intravenous (IV)</description>
    <arm_group_label>Treatment with TBI</arm_group_label>
    <other_name>fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Total Body Irradiation</intervention_name>
    <description>total body irradiation (300 cGy) with thymic shielding will be given six days before the stem cells are given (day -6). Thymic shielding is done by placing a piece of lead on the chest during the irradiation treatment so that the irradiation beams do not go to the thymus.</description>
    <arm_group_label>Treatment with TBI</arm_group_label>
    <other_name>Radiation Therapy, Therapeutic radiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bone Marrow Transplantation</intervention_name>
    <description>A target of 5 * 10^6/kg and a minimum of 4 * 10^6 CD34+ cell/kg recipient weight will be collected by apheresis and used for transplant. In most cases this dose will be recovered in a single apheresis; however, a second or rarely third apheresis performed on the following days may be required to achieve the minimum dose.</description>
    <arm_group_label>Treatment with TBI</arm_group_label>
    <other_name>Stem Cell transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>Patients will receive MMF therapy beginning on day -3 through day +30 or for 7 days after engraftment, whichever day is later, if no acute graft-versus-host disease (GVHD). Engraftment is defined as 1st day of 3 consecutive days of absolute neutrophil count [ANC] &gt; 0.5 * 10^9/L. MMF will be given at a dose of 15 mg/kg/dose every 8 hours by mouth(to a maximum dose of 1 gram).</description>
    <arm_group_label>Treatment with TBI</arm_group_label>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Sirolimus will be administered starting at day -3 with 8mg-12mg mg oral loading dose followed by single dose 4 mg/day with a target serum concentration of 3 to 12 mg/mL by high-performance liquid chromatography (HPLC). Levels are to be monitored 3 times/week in the first 2 weeks, weekly until day +60, and as clinically indicated until day +100 post-transplantation. In the absence of acute GVHD sirolimus may be tapered starting at day +100 and eliminated by day +180 post-transplantation.</description>
    <arm_group_label>Treatment with TBI</arm_group_label>
    <other_name>Rapamycin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Meeting the definition of standard risk or high risk Fanconi anemia as defined in the next
        two sections:

          -  Standard risk patients must be &lt;18 years of age with a diagnosis of Fanconi anemia
             with aplastic anemia (AA), myelodysplastic syndrome without excess blasts, or high
             risk genotype as defined below:

               -  Aplastic anemia is defined as having at least one of the following when not
                  receiving growth factors or transfusions:

                    -  platelet count &lt;20 * 10^9/L

                    -  ANC &lt;5 * 10^8/L

                    -  Hemoglobin &lt;8 g/dL

               -  Myelodysplastic syndrome (MDS) with multilineage dysplasia with or without
                  chromosomal anomalies

               -  High risk genotype (e.g. IVS-4 or exon 14 FANCC mutations, or BRCA1 or 2
                  mutations)

          -  High risk patients must have one or more of the following high risk features:

               -  Advanced MDS (≥ 5% blast) or acute leukemia

               -  Require additional HSCT for graft failure

               -  History at any time of systemic fungal or gram negative infection

               -  Severe renal disease with a creatinine clearance &lt;40 mL/min

               -  Age &gt; 18 years

          -  Very high risk patients must have Advanced MDS (≥ 5% blast) or acute leukemia after
             initial hematopoietic stem cell transplant (HSCT)

          -  Patients must have an appropriate source of stem cells. Patients and donors will be
             typed for HLA-A, B, C and DRB1 using high resolution molecular typing.

          -  Adequate major organ function including:

               -  Cardiac: ejection fraction &gt;45%

               -  Hepatic: bilirubin, AST or ALT, ALP &lt;5 x normal

               -  Karnofsky performance status &gt;70% or Lansky &gt;50 (if &lt; 16 years of age)

          -  Women of child-bearing age must be using adequate birth control and have a negative
             pregnancy test.

          -  Written consent.

        Exclusion Criteria:

          -  Available HLA-genotypically identical related donor in standard risk patients.

          -  Active central nervous system (CNS) leukemia at time of study enrollment.

          -  History of squamous cell carcinoma of the head/neck/cervix within previous 2 years.

          -  Prior radiation therapy that prevents further total body irradiation (TBI).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margaret L MacMillan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Margaret L MacMillan, M.D.</last_name>
    <phone>612-626-2778</phone>
    <email>macmi002@umn.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Minnesota Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret L MacMillan, M.D.</last_name>
      <phone>612-626-2778</phone>
      <email>macmi002@umn.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 14, 2006</study_first_submitted>
  <study_first_submitted_qc>July 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2006</study_first_posted>
  <last_update_submitted>December 3, 2017</last_update_submitted>
  <last_update_submitted_qc>December 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bone Marrow transplant</keyword>
  <keyword>stem cell transplant</keyword>
  <keyword>cord blood transplant</keyword>
  <keyword>total body irradiation</keyword>
  <keyword>thymic shielding</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Fanconi Anemia</mesh_term>
    <mesh_term>Fanconi Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

